| Year |
Citation |
Score |
| 2020 |
Ludwik KA, Sandusky ZM, Stauffer KM, Li Y, Boyd KL, O'Doherty GA, Stricker TP, Lannigan DA. RSK2 Maintains Adult Estrogen Homeostasis by Inhibiting ERK1/2-Mediated Degradation of Estrogen Receptor Alpha. Cell Reports. 32: 107931. PMID 32697984 DOI: 10.1016/J.Celrep.2020.107931 |
0.309 |
|
| 2020 |
Lee K, Guerrero-Zotano A, Hanker A, Servetto A, Sudhan D, Formisano L, Jansen V, González-Ericsson P, Sanders M, Stricker T, Cantley L, Arteaga C. Abstract GS6-06: A neoadjuvant trial with letrozole identifies PRR11 in the 17q23 amplicon as a mechanism of resistance to endocrine therapy in ER-positive breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs6-06 |
0.371 |
|
| 2020 |
Rahman SJ, Chu S, Zhao S, Zou Y, Hui A, Stricker T, Diehn M, Massion PP. Abstract 1137: Deep targeted and whole exome sequencing identifies driver mutations in the airway epithelium of individuals at high risk for lung cancer Cancer Research. 80: 1137-1137. DOI: 10.1158/1538-7445.Am2020-1137 |
0.316 |
|
| 2019 |
Bergdorf KN, Ferguson DC, Mehrad M, Ely K, Stricker T, Weiss VL. Papillary thyroid carcinoma behavior: clues in the tumor microenvironment. Endocrine-Related Cancer. PMID 30965283 DOI: 10.1530/Erc-19-0074 |
0.305 |
|
| 2018 |
Guerrero-Zotano A, Stricker T, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Pérez-Fidalgo JA, Lluch A, Llombart-Cussac A, et al. ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29581135 DOI: 10.1158/1078-0432.Ccr-17-2904 |
0.36 |
|
| 2018 |
Hebron KE, Li EY, Arnold Egloff SA, von Lersner AK, Taylor C, Houkes J, Flaherty DK, Eskaros A, Stricker TP, Zijlstra A. Alternative splicing of ALCAM enables tunable regulation of cell-cell adhesion through differential proteolysis. Scientific Reports. 8: 3208. PMID 29453336 DOI: 10.1038/S41598-018-21467-X |
0.362 |
|
| 2018 |
Gonzalez-Ericsson P, Estrada M, Formisano L, Jansen V, Mayer I, Rexer B, Abramson V, Levy M, Balko J, Stricker T, Arteaga C, Sanders M. Abstract PD4-07: Genenomic landscape of breast cancers with FGFR1 amplification and FGFR1/CCND1 co-amplification revealed by targeted capture next generation sequencing Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Pd4-07 |
0.383 |
|
| 2017 |
Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, et al. Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science Translational Medicine. 9. PMID 28794284 DOI: 10.1126/Scitranslmed.Aai7993 |
0.372 |
|
| 2017 |
Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, ... ... Stricker T, et al. Association of FGFR1 with ERαmaintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28751448 DOI: 10.1158/1078-0432.Ccr-17-1232 |
0.37 |
|
| 2017 |
Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Gianni L, Koch JP, Tyson DR, Sanchez V, Rexer BN, Sanders M, Zhao Z, Stricker T, Arteaga CL. Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2+ breast cancer. Cancer Research. PMID 28396358 DOI: 10.1158/0008-5472.Can-16-2808 |
0.341 |
|
| 2017 |
Stricker TP, Brown CD, Bandlamudi C, McNerney M, Kittler R, Montoya V, Peterson A, Grossman R, White KP. Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression. Plos Genetics. 13: e1006589. PMID 28263985 DOI: 10.1371/Journal.Pgen.1006589 |
0.349 |
|
| 2017 |
Guerrero A, Stricker T, Hutchinson K, Formisano L, Giltnane J, Fidalgo A, Schwarz L, Gavila J, Guillen V, Lluch A, Ruiz A, Arteaga C. Abstract P2-10-01: Genomic profiling of residual ER+ breast cancers treated with prolonged neoadjuvant letrozole reveals novel alterations in clinically resistant tumors Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P2-10-01 |
0.357 |
|
| 2017 |
Sowder M, Ludwik K, Pasic L, Brenin, Stricker T, Macara I, Lannigan D. Abstract P1-06-05: Breast cancer organoid cultures preserve intra-tumor heterogeneity and reveal intrinsically resistant phenotypes to standard chemotherapies Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-06-05 |
0.355 |
|
| 2017 |
Baras AS, Stricker T. Abstract LB-105: Characterization of total mutational burden in the GENIE cohort: Small and large panels can provide TMB information but to varying degrees Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-105 |
0.317 |
|
| 2016 |
Williams M, Lee L, Hicks DJ, Joly MM, Elion D, Rahman B, McKernan C, Sanchez V, Balko JM, Stricker T, Estrada MV, Cook RS. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade. Molecular Cancer Research : McR. PMID 28039357 DOI: 10.1158/1541-7786.Mcr-16-0280-T |
0.354 |
|
| 2016 |
Shaver TM, Lehmann BD, Beeler JS, Li CI, Li Z, Jin H, Stricker TP, Shyr Y, Pietenpol JA. Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies. Cancer Research. PMID 27231203 DOI: 10.1158/0008-5472.Can-16-0058 |
0.344 |
|
| 2016 |
Williams MM, Lee L, Morrison MM, McKernan C, Sanchez V, Hicks D, Stricker T, Cook RS. Abstract B07: Mcl-1-mediated resistance to ABT-263 is combated by mTOR inhibition in luminal breast cancers Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B07 |
0.356 |
|
| 2016 |
Guerrero-Zotano A, Stricker T, Hutchinson KE, Formisano L, Giltnane J, Ruiz A, Arteaga CL. Abstract 4508: Genomic profiling of ER+ breast cancers treated with prolonged neoadjuvant letrozole reveal a high frequency of NOTCH2 mutations in clinically resistant tumors Cancer Research. 76: 4508-4508. DOI: 10.1158/1538-7445.Am2016-4508 |
0.364 |
|
| 2016 |
Hanker AB, Estrada MV, Zhao J, Cheng F, Moore PD, Tyson D, Sanchez V, Rexer BN, Sanders M, Zhao Z, Stricker TP, Arteaga CL. Abstract 302: ECM/Integrin signaling promotes resistance to the combination of HER2 and PI3K inhibitors in HER2+, PIK3CA-mutant breast cancer Cancer Research. 76: 302-302. DOI: 10.1158/1538-7445.Am2016-302 |
0.316 |
|
| 2015 |
Barham W, Chen L, Tikhomirov O, Onishko H, Gleaves L, Stricker TP, Blackwell TS, Yull FE. Aberrant activation of NF-κB signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ. Bmc Cancer. 15: 647. PMID 26424146 DOI: 10.1186/S12885-015-1652-8 |
0.306 |
|
| 2015 |
Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, et al. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer. Molecular & Cellular Proteomics : McP. 14: 1959-76. PMID 25953087 DOI: 10.1074/Mcp.M115.049783 |
0.341 |
|
| 2014 |
Li G, Ci W, Karmakar S, Chen K, Dhar R, Fan Z, Guo Z, Zhang J, Ke Y, Wang L, Zhuang M, Hu S, Li X, Zhou L, Li X, ... ... Stricker T, et al. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell. 25: 455-68. PMID 24656772 DOI: 10.1016/J.Ccr.2014.02.007 |
0.333 |
|
| 2014 |
Hanker AB, Bulen B, Brewer MR, Young CD, Farrar KM, Cook RS, Stricker TP, Arteaga CL. Abstract 1822: HER2/PIK3CAH1047R transgenic tumors develop acquired resistance to triple therapy with trastuzumab, pertuzumab, and PI3K inhibitors via multiple mechanisms Cancer Research. 75: 1822-1822. DOI: 10.1158/1538-7445.Sabcs14-Pd5-8 |
0.345 |
|
| 2014 |
Young CD, Zimmerman LJ, Gatza ML, Morrison MM, Whitwell CA, Bhola NE, Hanker AB, Stricker T, Patel P, Brantley-Sieders DM, Perou CM, Park BH, Liebler DC, Cook RS, Arteaga CL. Abstract 970: Mass spectrometry analysis of PIK3CA mutant mammary epithelial cells identifies EGFR as a paracrine effector of PI3K in basal-like breast cancer Cancer Research. 74: 970-970. DOI: 10.1158/1538-7445.Am2014-970 |
0.368 |
|
| 2013 |
Balko JM, Stricker TP, Arteaga CL. The genomic map of breast cancer: which roads lead to better targeted therapies? Breast Cancer Research : Bcr. 15: 209. PMID 23905624 DOI: 10.1186/Bcr3435 |
0.315 |
|
| 2013 |
Brägelmann J, Dagogo-Jack I, El Dinali M, Stricker T, Brown CD, Zuo Z, Khattri A, Keck M, McNerney ME, Longnecker R, Bieging K, Kocherginsky M, Alexander K, Salgia R, Lingen MW, et al. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncology. 49: 525-33. PMID 23490885 DOI: 10.1016/J.Oraloncology.2013.02.003 |
0.302 |
|
| 2013 |
Papp G, Changchien YC, Péterfia B, Pecsenka L, Krausz T, Stricker TP, Khoor A, Donner L, Sápi Z. SMARCB1 protein and mRNA loss is not caused by promoter and histone hypermethylation in epithelioid sarcoma. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 26: 393-403. PMID 23174932 DOI: 10.1038/Modpathol.2012.190 |
0.308 |
|
| 2013 |
Keck MK, Zuo Z, Khattri A, Brown CD, Stricker T, Weichselbaum RR, Lingen MW, Cohen EE, White KP, Vokes EE, Hammerman PS, Seiwert TY. Genomic profiling of kinase genes in head and neck squamous cell carcinomas to identify potentially targetable genetic aberrations in FGFR1/2, DDR2, EPHA2, and PIK3CA. Journal of Clinical Oncology. 31: 6010-6010. DOI: 10.1200/Jco.2013.31.15_Suppl.6010 |
0.352 |
|
| 2013 |
Young CD, Zimmerman LJ, Whitwell CA, Hanker AB, Stricker T, Brantley-Sieders DM, Park BH, Liebler DC, Cook RS, Arteaga CL. Abstract B015: Knock-in of PIK3CA mutations in MCF10A mammary epithelial cells modifies their proteomic profile to resemble basal-like breast cancer and stimulate EGFR-dependent cell proliferation Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-B015 |
0.364 |
|
| 2013 |
Giltnane J, Balko J, Wang K, Kuba M, Mehndi M, Stricker T, Sanders M, Yelensky R, Stephens P, Miller V, Arteaga C. Abstract PD3-1: Serial next generation sequencing (NGS) of poor prognosis luminal tumors across treatment history reveals both de novo and acquired alterations potentially associated with endocrine resistance Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Pd3-1 |
0.383 |
|
| 2012 |
Seiwert TY, Keck MK, Zuo Z, Khattri A, Brown C, Stricker T, Rieke D, Lingen MW, Cohen EEW, White KP, Vokes EE. Genomic profiling of a clinically annotated cohort of locoregionally advanced head and neck cancers (HNC) treated with definitive chemoradiotherapy. Journal of Clinical Oncology. 30: 5517-5517. DOI: 10.1200/Jco.2012.30.15_Suppl.5517 |
0.348 |
|
| 2010 |
Braegelmann J, Stricker T, Brown C, Dinali ME, Zou X, Vokes E, White K, Seiwert T. 255 Transcriptome sequencing of upper aerodigestive tract cancer cell lines to reveal potential therapeutic targets European Journal of Cancer Supplements. 8: 84. DOI: 10.1016/S1359-6349(10)71961-3 |
0.304 |
|
| 2009 |
Zou Z, Schmaier AA, Cheng L, Mericko P, Dickeson SK, Stricker TP, Santoro SA, Kahn ML. Negative regulation of activated alpha-2 integrins during thrombopoiesis. Blood. 113: 6428-39. PMID 19258597 DOI: 10.1182/Blood-2008-08-175356 |
0.562 |
|
| 2009 |
Liu J, Ghanim M, Xue L, Brown CD, Iossifov I, Angeletti C, Hua S, Nègre N, Ludwig M, Stricker T, Al-Ahmadie HA, Tretiakova M, Camp RL, Perera-Alberto M, Rimm DL, et al. Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science (New York, N.Y.). 323: 1218-22. PMID 19164706 DOI: 10.1126/Science.1157669 |
0.324 |
|
| 2009 |
Dinali ME, Braegelmann J, Stricker T, Brown C, Salgia R, Vokes E, White K, Seiwert T. Abstract A207: Whole transcriptome profiling in upper aerodigestive tract cancers Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A207 |
0.349 |
|
| 2006 |
Edelson BT, Stricker TP, Li Z, Dickeson SK, Shepherd VL, Santoro SA, Zutter MM. Novel collectin/C1q receptor mediates mast cell activation and innate immunity. Blood. 107: 143-50. PMID 16166590 DOI: 10.1182/Blood-2005-06-2218 |
0.568 |
|
| 2006 |
DICKESON S, STRICKER T, BENTON A, PAN Y, SANTORO S. Affinity modulation of the α2 integrin I domain Matrix Biology. 25: S52-S52. DOI: 10.1016/J.Matbio.2006.08.144 |
0.517 |
|
| 2003 |
Santoro SA, Stricker TP. Location, location, location: targeting the endothelium Blood. 101: 3761-3761. DOI: 10.1182/Blood-2003-03-0764 |
0.527 |
|
| 2001 |
Dumin JA, Dickeson SK, Stricker TP, Bhattacharyya-Pakrasi M, Roby JD, Santoro SA, Parks WC. Pro-collagenase-1 (matrix metalloproteinase-1) binds the alpha(2)beta(1) integrin upon release from keratinocytes migrating on type I collagen. The Journal of Biological Chemistry. 276: 29368-74. PMID 11359786 DOI: 10.1074/Jbc.M104179200 |
0.557 |
|
| 2001 |
Stricker TP, Dumin JA, Dickeson SK, Chung L, Nagase H, Parks WC, Santoro SA. Structural analysis of the alpha(2) integrin I domain/procollagenase-1 (matrix metalloproteinase-1) interaction. The Journal of Biological Chemistry. 276: 29375-81. PMID 11359774 DOI: 10.1074/Jbc.M102217200 |
0.556 |
|
| Show low-probability matches. |